SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the aPCC-emicizumab safety study is to prospectively investigate the safety
and hemostatic efficacy of a personalized dose of aPCC in children and adults with hemophilia
A and inhibitors on emicizumab prophylaxis during acute bleeding events or prior to
procedures.